Search

Background: Major depressive disorder (MDD) is frequently chronic and relapsing. The use of maintenance or continuation transcranial magnetic stimulation (TMS) has received clinical and some research support. Objective: To conduct a case series study to report the outcomes of once-weekly (OW) or once-fortnightly (OF) continuation TMS in a real-life setting. Methods: We offered OW or OF TMS sessions to patients with MDD in remission or partial remission/relapse. Results: Ten patients received OW TMS and four received OF TMS, for 8 to 46 weeks. No patients in either group who were in remission or partial remission at baseline experienced a relapse. Improvements in HAMD6 and CGI-S scores were statistically significant or of borderline significance for the total sample and the OW group. Conclusions: This naturalistic, open-label observational study indicates that OW TMS is effective as maintenance therapy in MDD, while also offering some support for OF TMS maintenance in preventing relapse. [ABSTRACT FROM AUTHOR]

Objective: To examine reports of Transcranial Magnetic Stimulation (TMS) during pregnancy for evidence of fetal risk.Method: PubMed was used to locate relevant literature for the years 1998-2020 and reference lists were examined for materials not located electronically.Results: Ten reports were located dealing with 67 births over 20 years. Stimulation was applied is all trimesters, at low and high frequency, and as intermittent theta-burst stimulation. No mother or baby experienced a serious event.Conclusions: Certainty awaits large, standardized studies. However, the available reports provide no evidence that TMS to mother during pregnancy has detrimental effects on the fetus. [ABSTRACT FROM AUTHOR]

Objective: To determine the impact of clustered maintenance transcranial magnetic stimulation (TMS) on irritability occurring in treatment-resistant major depressive disorder (MDD).Method: A naturalistic study of 106 courses that includes pre- and posttreatment assessments of subjective and objective depression and a subjective measure of irritability developed for this study.Results: Forty-six participants (35 females), mean age 43.2 years (14.3), completed 106 courses. There was a significant reduction in irritability and depression scores (p < .001). The change in irritability scores was significantly correlated with the change in depression scores, r = .40, p < .001.Conclusion: TMS has the capacity to reduce the irritability co-occurring with treatment-resistant MDD, known to be responsive to TMS. This increases the possibility of using TMS in the treatment of irritability co-occurring with other disorders or standing alone (should irritability be categorized as a stand-alone disorder). [ABSTRACT FROM AUTHOR]

Background: Various TMS protocols have been described, none is appropriate in all circumstances. Objective: To describe the response of a person with acute MDD treated with TMS who was only available for treatment on 3 consecutive days per week. Method: 5 treatment sessions were provided over 3 days – this was provided 4 times, separated by no-treatment periods of 4 days. HAMD6, CSI-S and VAS for depression were completed on the first and last day of each 3-day treatment series. Results: Remarkable improvement; the HAMD6 fell from 12 (severe depression) to 0, the CGI-S fell from 5 (Markedly ill) to 1 (Normal, not mentally ill) and the VAS fell by 98%. There was clear improvement during the last 3 treatment series, as well as during all 3 no-treatment periods. Conclusion: Should these findings be replicated, an additional, useful protocol may be established. [ABSTRACT FROM AUTHOR]